BioRestorative Therapies, Inc. (BRTX) AI Stock Analysis

BioRestorative Therapies, Inc. is a life sciences company developing regenerative medicine products and therapies utilizing adult stem cells. Its core developmental programs include brtxDisc, centered on lead cell therapy candidate BRTX-100, which is formulated from autologous cultured mesenchymal stem cells extracted from bone marrow and has completed Phase 1 clinical trials for painful lumbosacral disc disorders. The company is also advancing ThermoStem, a preclinical cell-based therapy targeting obesity and metabolic disorders using brown adipose-derived stem cells, as well as an investigational curved needle device. It maintains strategic research and development collaborations with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania.

Annual revenue increased from $46,000 in FY2021 to $119,800 in FY2022 and $145,800 in FY2023, reaching $401,000 in FY2024 before revenue fell 10.3% to $359,700 in FY2025. Between FY2020 and FY2025, the 5-year revenue CAGR was 36.1%. Gross margin was 100.0% from FY2021 through FY2023, then moved to 93.0% in FY2024 and 93.4% in FY2025. Net income stood at -$44.3M in FY2021, -$13.2M in FY2022, -$10.4M in FY2023, -$9.0M in FY2024, and -$14.2M in FY2025, with R&D expense rising to $10.1M in FY2025. For the trailing twelve months ending March 31, 2026, revenue was $357,870, quarterly revenue fell 7.3% year-over-year, and operating margin was -14612.6%.

As of March 31, 2026, BioRestorative Therapies held $3.6M in cash and short-term investments, total debt of $34,515, and net cash of $3.6M. Total assets stood at $4.6M and shareholders' equity was $3.0M, supporting a current ratio of 2.35 and a debt-to-equity ratio of 0.01. Free cash flow for FY2025 was -$10.9M, based on operating cash flow of -$10.8M and capital expenditures of $116,069. In FY2025, the company paid dividends of $270,573, while its share count expanded 403.6% over 5 years.

BioRestorative Therapies carries a market capitalization of $2.1M and an enterprise value of -$9.5M. The stock trades at a price-to-sales multiple of 5.9x, compared to a median of 4.1x for its US-listed Healthcare peers. Its enterprise value-to-revenue ratio is 192.1x, and EV to EBITDA is 0.1x compared to the US-listed Healthcare peer median EV to EBITDA of 12.0x. The company's price-to-book ratio is 1.2x. Over the past year, the S&P 500 (SPY) returned 16.8%, and over 5 years returned 83.0%, while BRTX closed at $1.54 on October 16, 2026, within its 52-week range of $1.28 to $2.93.

Analyst coverage includes 1 Strong Buy and 1 Hold rating. The mean price target is $300.00, representing a 19380.5% premium to the last close of $1.54. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $310,000 and an EPS of -$13.20. For the following fiscal year, 1 analyst expects revenue to reach $1.5M, reflecting 383.9% revenue growth, with EPS projected at -$10.40. BioRestorative Therapies recorded 4 EPS beats over the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of BioRestorative Therapies, Inc. (BRTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BRTX income statement, BRTX balance sheet, BRTX key metrics, BRTX analyst forecast, BRTX chart. See the BRTX stock overview for the latest quote and news.